CLINICAL TRIALS AND OBSERVATIONS Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study
نویسندگان
چکیده
1Academic Haematology, Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 2Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom; 3Department of Haematology, Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust, Newcastle upon Tyne, United Kingdom; 4Department of Haematology, Anchor Unit, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, United Kingdom; 5Department of Haematology, Sunderland Royal Infirmary, City Hospitals Sunderland NHS Foundation Trust, Sunderland, United Kingdom; 6Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; 7Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom; and 8Department of Pathology, Western General Hospital, NHS Lothian, University of Edinburgh, Edinburgh, United Kingdom
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS A prospective study of mediastinal gray-zone lymphoma
• MGZL with pathologic features in between NSHL and PMBL is very rare and most frequently occurs in young patients. • A prospective study of DA-EPOCH-R without mediastinal radiation in MGZL demonstrated an inferior outcome compared to patients with PMBL. MediastinalB-cell lymphomaspresent in themediastinumandaremost frequent in young patients. Nodular sclerosis Hodgkin lymphoma (NSHL) and prima...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive nonHodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease developing during first-line therapy or after a complete or partial remission had been achieved. Patients received 6 or 8 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) administered every 2 weeks (CHO...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal. At dose level 1 (DL1), course 1 consisted of cyclophosphamide 1500 mg/m2, do...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO
A prospective, multicenter, randomized trial was undertaken to compare the efficacy and toxicity of adriamycin with mitoxantrone within a 6-drug combination chemotherapy regimen for elderly patients (older than 60 years) with highgrade non-Hodgkin lymphoma (HGL) given for a minimum of 8 weeks. A total of 516 previously untreated patients aged older than 60 years were randomized to receive 1 of ...
متن کامل